AU Patent

AU2022206421A1 — Methods and compositions for rapid delivery of anti-seizure therapeutics

Assigned to Neurelis Inc · Expires 2023-07-13 · 3y expired

What this patent protects

Compositions for intranasal delivery of benzodiazepines and methods for their use to treat and prevent seizures are provided. The compositions deliver rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration. Additionally, use of …

USPTO Abstract

Compositions for intranasal delivery of benzodiazepines and methods for their use to treat and prevent seizures are provided. The compositions deliver rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration. Additionally, use of the compositions for the treatment of seizure clusters increases the time to a second seizure and duration of the interseizure cluster interval.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022206421A1
Jurisdiction
AU
Classification
—
Expires
2023-07-13
Drug substance claim
No
Drug product claim
No
Assignee
Neurelis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.